BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BioNexus Gene Lab Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.23+0.03 (+2.23%)
Close on Oct 19, 2026
- Market cap
- $2.97M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.90 (−76.06%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
BioNexus Gene Lab Corp saw revenue fall 67.3% to $3.13M over the twelve months to Jun 30, 2026. Free cash flow was -$853.60K.
Revenue
$3.13M
-67.3% vs. a year earlier
Operating income
-$2.56M
TTM Q2 2026
Free cash flow
-$853.60K
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.97M
- P/E ratio
- –
- Price to sales
- 0.95
- Price to book
- 0.38
- Dividend yield
- –
- Free cash flow yield
- -28.76%
Fundamentals
- Revenue
- $3.13M
- Net income
- -$2.58M
- Free cash flow
- -$853.60K
- Book value per share
- $3.22
- Diluted shares
- 2M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$3.13M-67.3% YoY
Gross profit
$385.89K-71.4% YoY
Operating income
-$2.56M
Net income
-$2.58M
EPS, diluted
–
Free cash flow
-$853.60K
Reported periodTrailing twelve months